Molecular genetic approaches to non-melanoma and melanoma skin cancer

Clinical and Experimental Dermatology

Volumn 21, Issue 4, 1996, Pages 253-262

  Rees, J L ^a   Healy, E ^a  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

HUMAN; MELANOMA; MOLECULAR GENETICS; MUTATION; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SUPPRESSOR GENE;

BASAL CELL NEVUS SYNDROME; CARCINOMA, SQUAMOUS CELL; CHROMOSOMES, HUMAN, PAIR 9; GENES, P53; GENES, TUMOR SUPPRESSOR; HUMANS; MELANOMA; ONCOGENES; SKIN NEOPLASMS;

EID: 0029836864     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2230.1996.tb00089.x     Document Type: Review

References (141)

1. Weinberg RA. Oncogenes, tumour suppressor genes, and cell transformation: Trying to put it all together. In: Brugge J, Curran T, Harlow E, McCormiek F, eds. Origins of Uuman Cancer. New York: Cold Spring Harbour Laboratory Press, 1991: 1-16.
2. Varmus H, Weinberg RA. Genes and the Biology of Cancer. New York: Scientific American Library, 1993: 1.
3. Vogelstein B, Kinzler KW. The multistep nature of cancer. Review. Trends Genet 1993; 9: 138-41.
4. Knudson A. Genetic events in human carcinogenesis. In: Brugge J, Curran T, Harlow E, McCormick F eds. Origins of Human Cancer. New York: Cold Spring Harbour Laboratory Press, 1991: 17-26.
5. Eng C, Ponder BAJ. The role of gene mutations in the genesis of familial cancers. FASEB J 1993; 7: 910-19.
6. Gailani MR, Bale SJ, Leffel DJ et al. Developmental defects in Gorlin's syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69: 111-17.
7. Kamb A, Nelleke AG, Weaver-Feldhaus J et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436-40.
8. Kamb A, Shattuck-Eidens D, Eeles R et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet 1994; 8: 22-6.
9. Quinn AG, Sikkink S, Rees JL. Delineation of two distinct deleted regions on chromosome 9 in human non-melanoma skin cancers. Genes Chromosomes Cancer 1994; 11: 222-5.
10. Quinn AG, Sikkink S, Rees JL. Basal cell carcinomas and squamous cell carcinomas show distinct patterns of chromosome loss. Cancer Res 1994; 54: 4756-9.
11. van der Riet P, Karp D, Farmer E et al. Progression of basal cell carcinoma through loss of chromosome 9q and inactivation of a single p53 allele. Cancer Res 1994; 54: 25-7.
12. Hinds PW, Weinberg RA. Tumor suppressor genes. Curr Opin Genet Dev 1994; 4: 135-41.
13. Yuspa SH, Dlugosz AA, Cheng CK et al. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol 1994; 103 (Suppl.): 90-5S.
14. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-9.
15. Klein G. Genes that can antagonize tumor development. FASEB J 1993; 7: 821-5.
16. Harris H. The analysis of malignancy by cell fusion: the position in 1988. Cancer Res 1988; 48: 3302-6.
17. Anderson MJ, Stanbridge EJ. Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 1993; 7: 826-33.
18. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
19. Yokota J, Sugimura T. Multiple steps in carcinogenesis involving alterations of multiple tumor suppressor genes. FASEB J 1993; 7: 920-5.
20. Kraemer KH, Lee M-M, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer: The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130: 1018-21.
21. Tanaka K, Wood RD. Xeroderma pigmentosum and nucleotide excision repair of DNA. TIBS 1994; 19: 83-6.
22. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266: 1954-6.
23. Honchel R, Hailing KC, Schaid DJ, Pittelkow M, Thibodeau SN. Microsatellite instability in Muir Torre syndrome. Cancer Res 1994; 54: 1159-63.
24. Kolodner RD, Hall NR, Lipford J et al. Structure of the human MSH2 locus and analysis of two Muir-Torre kindreds for msh2 mutations. Genomics 1994; 24: 516-26.
25. Quinn AG, Healy E, Rehman I, Sikkink S, Rees JL. Microsatellite instability in human non-melanoma and melanoma skin cancer. J Invest Dermatol 1995; 104: 309-12.
26. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genet 1995; 11: 328-30.
27. Carey FA. Measurement of nuclear DNA content in histological and cytological specimens: principles and applications. (Review). J Pathol 1994; 172: 307-12.
28. Newton JA, Camplejohn RS, McGibhon DH. A flow cytometric study of the significance of DNA aneuploidy in cutaneous lesions. Br J Dermatol 1987; 117: 169-74.
29. Frentz G, Moller U. Clonal heterogeneity in curetted human epidermal cancers and precancers analysed by flow cytometry and compared with histology. Br J Dermatol 1983; 109: 173-81.
30. Herzberg AJ, Kerns BJ, Pollack V, Kinney RB. DNA image cytometry of keratoacanthoma and squamous cell carcinoma. J Invest Dermatol 1991; 97: 495-500.
31. Fortier-Beaulieu M, Laquerriere A, Thomine E, Lauret P, Hemet J. DNA flow-cytometric analysis of basal cell carcinomas and its relevance to their morphological differentiation: a retrospective study. Dermatology 1994; 188: 94-9.
32. Seidman JD, Berman JJ, Moore GW, Yetter RA. Multiparameter DNA flow cytometry of keratoacanthoma. Analyt Quant Cytol Histol 1992; 14: 113-19.
33. Chi H, Kawachi Y, Otsuka F. Xeroderma pigmentosum variant: DNA ploidy analysis of various skin tumors and normalappearing skin in a patient. Int J Dermatol 1994; 33: 775-8.
34. Stephenson TJ, Cotton DW. Flow cytometric comparison of keratoacanthoma and squamous cell carcinoma (letter). Br J Dermatol 1988; 118: 582-3.
35. Rehman I, Quinn AG, Healy E, Rees JL. High frequency of loss of heterozygosity in actinic keratoses, a usually benign disease. Lancet 1994; 344: 788-9.
36. Heim S, Jin YS, Mandahl N et al. Multiple unrelated clonal chromosome abnormalities in an in situ squamous cell carcinoma of the skin (see comments). Cancer Genet Cytogenet 1988; 36: 149-53.
37. Heim S, Mertens F, Jin YS et al. Diverse chromosome abnormalities in squamous cell carcinomas of the skin. Cancer Genet Cytogenet 1989; 39: 69-76.
38. Heim S, Mitelman F. Tumors of the skin. In: Heim S, Mitelman F, eds. Cancer Cytogenetics. New York: Wiley-Liss, 1995: 465-75.
39. Barbacid M. Ras genes. (Review). Ann Rev Biochem 1987; 56: 779-827.
40. Egan SE, Weinberg RA. The pathway to signal achievement. Nature 1993; 365: 781-3.
41. Burns PA, Bremner R, Balmain A. Genetic changes during mouse skin tumorigenesis. (Review). Environ Health Perspectives 1991; 93: 41-4.
42. Fowlis DJ, Balmain A. Oncogenes and tumour suppressor genes in transgenic mouse models of neoplasia. (Review), Eur J Cancer 1993; 29A: 638-45.
43. Anathaswamy HN, Pierceall WE. Molecular alterations in human skin tumors. In: Klein-Szanto AJP, Anderson MW, Barrett JC, Slaga TJ, eds. Comparative Molecular Carcinogenesis. New York: Wiley-Liss, 1992; 61-84.
44. Campbell C, Quinn AG, Rees JL. Codon 12 Harvey-ras mutations are rare events in non-melanoma human skin cancer. Br J Dermatol 1993; 128: 111-14.
45. Campbell C, Rees JL. The role of ras gene mutations in murine and human skin carcinogenesis. Skin Cancer 1993; 8: 245-54.
46. Moles JP, Moyret C, Guillot B et al. p53 gene mutations in human epithelial skin cancers. Oncogene 1993; 8: 583-8.
47. Van der Schroeff J, Evers LM, Boot AJM, Bos JL. ras oncogene mutations in basal cell carcinomas and squamous cell carcinomas of human skin. J Invest Dermatol 1990; 94: 423-5.
48. Daya-Grosjean L, Robert C, Drougard C, Suarez H, Sarasin A. High mutation frequency in ras genes of skin tumors isolated from DNA repair deficient xeroderma pigmentosum patients. Cancer Res 1993; 53: 1625-9.
49. Ishizaki K, Tsujimura T, Nakai M et al. Infrequent mutation of the ras genes in skin tumors of xeroderma pigmentosum patients in Japan, Int J Cancer 1992; 50: 382-5.
50. Suarez HG, Daya-Grosjean L, Schlaifer D et al. Activated oncogenes in human skin tumors from a repair-deficient syndrome, xeroderma pigmentosum. Cancer Res 1989; 49: 1223-8.
51. Corominas M, Leon J, Kamino H, Cruz-Alverez M, Novick SC, Pellicer, A. Oncogene involvement in tumour regression: H-ras activation in the rabbit keratoacanthoma model. Oncogene 1991; 4: 645-51.
52. Corominas M, Kamino H, Leon J, Pellicer A. Oncogene activation in human benign tumors of the skin (keratoacanthomas): is H-ras involved in differentiation as well as proliferation? Proc Natl Acad Sci USA 1989; 86: 6372-6.
53. Cox LS, Lane DP. Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. BioEssays 1995; 17: 501-8.
54. Kastan MB, Canman K, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rer 1995; 14: 3-15.
55. Lane DP. p53 and human cancers. (Review). Br Med Bull 1994; 50: 582-99.
56. Lane DP. The regulation of p53 function: Steiner Award Lecture. Int J Cancer 1994; 57: 623-7.
57. Vousden K. Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 1993; 7: 872-9.
58. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253: 49-53.
59. Harris CC, Hollstein M. Clinical implications of the p53 tumor suppressor gene. N Engl J Med 1993; 329: 1318-27.
60. Zambetti GP, Levine AJ. A comparison of the biological activities of wild-type and mutant p53. FASEB J 1993; 7: 855-65.
61. Hann BC, Lane DP. The dominating effect of mutant p53. Nature Genet 1995; 9: 221-2.
62. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice, Nature Genet 1995; 9: 305-11.
63. Li FP. Molecular epidemiology of familial cancers. In: Brugge J, Curran T, Harlow E, McCormick F, eds. Origins of Human Cancer. A Comprehensive Reviem. New York: Cold Spring Harbor Laboratory Press, 1991: 211-18.
64. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion hut enhances malignant progression of chemically induced skin tumors. Cell 1993; 74: 813-22.
65. Brash DE, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991; 88: 10124-8.
66. Vogelstein B, Kinzler KW. Carcinogens leave fingerprints (news). Nature 1992; 355: 209-10.
67. Dumaz N, Stary A, Soussi T, Daya-Grosjean L, Sarasin A. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? (Review). Mutat Res 1994; 307: 375-86.
68. Ananthaswamy HN, Pierceall WE. Molecular mechanisms of ultraviolet radiation carcinogenesis. Photochem Photobiol 1990; 52: 1119-36.
69. Kanjilal S, Strom SS, Clayman GL et al. p53 mutations in nonmelanoma skin cancer of the head and neck: molecular evidence for field cancerization. Cancer Res 1995; 55: 3604-9.
70. Campbell C, Quinn AG, Ro YS, Angus B, Recs JL. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746-8.
71. Taguchi M, Watanabe S, Yashima K, Murakami Y, Sekiya T, Ikeda S. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. J Invest Dermatol 1994; 103: 500-3.
72. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-6.
73. Campbell C, Quinn AG, Angus B, Rees JL. The relation between p53 mutation and p53 immunostaining in non-melanoma skin cancer. Br J Dermatol 1993; 129: 235-41.
74. Ziegler A, Leffell DJ, Kunala S et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. Proc Natl Acad Sci USA 1993; 90: 4216-20.
75. Lrano Y, Asano T, Yoshimoto K et al. Frequent p53 accumulation in the chronically sun-exposed epidermis and clonal expansion of p53 mutant cells in the epidermis adjacent to basal cell carcinoma. J Invest Dermatol 1995; 104: 928-32.
76. Kubo Y, Urano Y, Yoshimoto K et al. p55 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. J Invest Dermatol 1994; 102: 440-4.
77. Wales MM, Biel MA, El Deiry W et al. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nature Med 1995; 1: 570-7.
78. Nakazawa H, English D, Randell PL et al. UV and skin cancer : Specific p53 gene mutation in normal skin as a biologically relevant exposure measurement. Proc Natl. Acad Sci USA 1994; 91: 360-4.
79. Young AR. The sunburn cell. Photodermatology 1987; 4: 127-34.
80. Bartek J, Bartkova J, Lukas J, Staskova Z, Vojtesek B, Lane DP. Immunohistochemical analysis ot the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. J Pathol 1993; 169: 27-34.
81. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p55. J Immunol Methods 1992; 151: 237-44.
82. Bartek J, Bartkova J, Yojtesek B et al. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-703.
83. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994; 172: 5-12.
84. Ro YS, Cooper PN, Lee JA et al. p53 protein expression in benign and malignant skin tumours. Br J Dermatol 1993; 128: 237-41.
85. Nagano T, Ueda M, Ichihashi M. Expression of p55 protein is an early event in ultraviolet light induced cutaneous squamous cell carcinogenesis. Arch Dermatol 1993; 129: 1157-61.
86. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathologic conditions. J Am Acad Dermatol 1993; 29: 741-8.
87. Shin DM, Kim J, Ro JY et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321-6.
88. McNutt NS, Saenx-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalities of p55 protein expression in cutaneous disorders. Arch Dermatol 1994; 130: 225-32.
89. Proby CM, Menage HduP, McGregor JM et al. p53 immunoreactivity in cutancous PUVA tumors is similar to that in other non-melanoma skin neoplasms. J Cutan Pathol 1993; 20: 435-41.
90. Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1992; 141: 25-9.
91. Stephenson TJ, Royds J, Silcocks PB, Blechen SS. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992; 127: 566-70.
92. McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalities of p53 protein expression in cutaneous disorders (editorial). (Review). Arch Dermatol 1994; 130: 225-32.
93. McGregor JM, Yu CC, Dublin EA, Levison DA, MacDonald DM. Aberrant expression of p53 tumour-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992; 127: 463-9.
94. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130: 181-5.
95. Sim CS, Slater S, McKee PH. Mutant p53 expression in solar keratoses : an immunohistochemical study. J Cutan Pathol 1992; 19: 302-8.
96. Urano Y, Oura H, Sakaki A et al. Immunohistological analysis of p53 expression in human skin tumors. J Dermatol Sci 1992; 4: 69-75.
97. Slater SD, McGrath JA, Hobbs C, Eady RAJ, McKee PH. Expression of mutant p53 gene in squamous carcinoma arising in patients with recessive epidermolysis bullosa. Histopathology 1992; 20: 237-41.
98. Lee Y-S, Teh M. p53 expression in pseudoepitheliomatous hyperplasia, keratoacanthoma, and squamous cell carcinoma of skin. Cancer 1994; 73: 2317-23.
99. McGregor JM, Farthing A, Crook T et al. Posttransplant skin cancer: A possible role for p53 gene mutation but not for oncogenic human papillomaviruses. J Am Acad Dermatol 1994; 30: 701-6.
100. Oram Y, Orengo I, Baer SC, Ocal T. p53 protein expression in squamous cell carcinomas from sun-exposed and non-sun-exposed sites. J Am Acad Dermatol 1994; 31: 417-22.
101. Kerschmann RL, McCalmont TH, LeBoit PE. p53 oncoprotein expression and proliferation index in keratoacanthoma and squamous cell carcinoma. Arch Dermatol 1994; 130: 181-6.
102. Urano Y, Arase S. Immunohistologic p53 expression in normal skin. J Am Acad Dermatol 1994; 31: 518.
103. Wynford-Thomas D. p53 in tumour pathology: can we trust immunocytochemistry? (editorial). J Pathol 1992; 166: 329-30.
104. Campbell C, Quinn AG, Angus B, Farr PM, Rees JL. Wave-length specific patterns of p53 induction in human skin following exposure to UV radiation. Cancer Res 1993; 53: 2697-9.
105. Hall PA, McKee PH, Menagé HduP, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-7.
106. Healy E, Reynolds NJ, Smith M, Campbell C, Farr PM, Rees JL. Dissociation between erythema and p53 expression in human skin: effects of UVB irradiation and skin irritants. J Invest Dermatol 1994; 103: 493-9.
107. Antoniades HN, Galanopoulos T, Neville-Golden J, Kiritsy CP, Lynch SE. p53 expression during normal tissue regeneration in response to acute cutaneous injury in swine. J Clin Invest 1994; 93: 2206-14.
108. Alberts B, Bray D, Lewis J et al. Molecular Biology of the Cell. New York: Garland Publishing, 1994.
109. Farndon PA, Mastro RGD, Evans DGR, Kilpatrick MW. Location of gene for Gorlin syndrome. Lancet 1992; 339: 581-2.
110. Goldstein AM, Stewart C, Bale AE, Bale SJ, Dean M. Localization of the gene for the nevoid basal cell carcinoma syndrome. Am J Hum Genet 1994; 54: 765-73.
111. Goudie DR, Yuille MAR, Leversha MA et al. Multiple self healing squamous epitheliomata (ESS1) mapped to chromosome 9q22-q31 in families with common ancestry, Nature Genet 1993; 3: 165-9.
112. Quinn AG, Campbell C, Healy E, Rees JL. Chromosome 9 allele loss occurs in both basal and squamous cell carcinomas of the skin. J Invest Dermatol 1994; 102: 300-3.
113. Takata M, Quinn AG, Hashimoto K, Rees JL. Low frequency of loss of heterozygosity at the nevoid basal cell carcinoma locus and other selected loci in appendageal tumours. J Invest Dermatol 1996; 106: 1141-4.
114. Lowry WS, Atkinson RJ. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma (letter; comment). Br J Dermatol 1993; 128: 708.
115. Waring AJ, Takata M, Rehman I, Rees JL. Loss of heterozygosity analysis of keratoacanthoma reveals multiple differences from cutaneous squamous cell carcinoma. Br J Cancer 1995; 73: 649-53.
116. Cowan JM, Halaban R, Francke U. Cytogenetic analysis from melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988; 80: 1159-64.
117. Van 't Veer LJ, Burgering BMT, Versteeg R et al. N-ras mutations in human cutaneous melanoma from sun exposed body sites. Mol Cell Biol 1989; 9: 3114-16.
118. Ball XJ, Yohn JJ, Morelli JG, Norris DA, Golitz LE, Hoeffler JP. ras mutations in human melanoma: a marker of malignant progression. J Invest Dermatol 1994; 102: 285-90.
119. Carr J, Mackie RM. Point mutations in the N-ras oncogene in malignant melanoma and congenital naevi. Br J Dermatol 1994; 131: 72-7.
120. Millikin D, Meese E, Vogelstein B, Witkowski C., Trent J. Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma. Cancer Res 1991; 51: 5449-53.
121. Fountain JW, Karayiorgou M, Ernstoff MS et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89: 10557-61.
122. Isshiki K, Elder DE, Guerry D, Linnenbach AJ. Chromosome 10 allelic loss in malignant melanoma. Genes. Chromosomes, Cancer 1993; 8: 178-84.
123. Herbst RA, Weiss J, Ehnis A, Cavenee WK, Arden KC. Loss of heterozygosity for 10q22-10qter in malignant melanoma progression. Cancer Res 1994; 54: 3111-14.
124. Herbst RA, Larson A, Weiss J, Cavenee WK, Hampton GM, Arden KC. A denned region of loss of heterozygosity at 11q23 in cutaneous malignant melanoma. Cancer Res 1995; 55: 2494-6.
125. Walker GJ, Palmer JM, Walters MK, Nancarrow DJ, Parsons PG, Hayward NK. Simple tandem repeat allelic deletions confirm the preferential loss of distal chromosome 6q in melanoma. Int J Cancer 1994; 58: 203-6.
126. Healy E, Rehman I, Angus B, Rees JL. Loss of heterozygosity in sporadic primary melanomas. Genes, Chromosomes, Cancer 1995; 12: 152-6.
127. Tomlinson IP, Gammack AJ, Stickland JE et al. Loss of heterozygosity in malignant melanoma at loci on chromosome 11 and 17 implicated in the pathogenesis of other cancers. Genes. Chromosomes, Cancer 1993; 7: 169-72.
128. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I, Rigby H, Rees JL. Allelotypes of primary cutaneous melanoma and benign melanocytic naevi. Cancer Res 1996; 56: 589-93.
129. Cannon-Albright LA, Goldgar DE, Meyer LJ et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1993; 258: 1148-52.
130. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
131. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitors in the development of cancer (Review). Blood 1995; 86: 841-54.
132. Gruis NA, van der Velden PA, Sandkuijl LA et al. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nature Genet 1995; 10: 351-3.
133. Hussussian CJ, Struewing JP, Goldstein AM et al. Germline p16 mutations in familial melanoma. Nature Genet 1994; 8: 15-21.
134. Ohta M, Nagai H, Shimizu M et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res 1994; 54: 5269-72.
135. Gruis NA, Weaver-Feldhaus J, Liu Q et al. Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol 1995; 146: 1199-206.
136. Merlo A, Gabrielson E, Mabry M, Vollmer R, Baylin SB, Sidransky D. Homozygous deletion on chromosome 9p and loss of heterozygosity on 9q, 6p, and 6q in primary human small cell lung cancer. Cancer Res 1994; 54: 2322-6.
137. Merlo A, Herman JG, Mao L et al. 5′OpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Med 1995; 1: 686-92.
138. Oastresana JS, Rubio M, Vazquez JJ et al. Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma. Int J Cancer 1993; 55: 562-5.
139. Hahn H, Wicking C, Zaphiropoulos PG et al. Mutations of the human homolog of drosophila patched in the neroid basal cell carcinoma syndrome. Cell 1996; 85: 841-51.
140. Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene tor the basal cell nevus syndrome. Science 1996; 272: 1668-71.
141. Gailani MR, Stahle-Backdahl M, Leffell DJ et al. The role of the human homologue of drosophila patched in sporadic basal cell carcinoma. Nature Genetics 1996; 13: 78-81.